Levosimendan

Generic Name: Levosimendan

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₂N_₆O

CAS Number: 141505-33-1

Unique Ingredient Identifier: C6T4514L4E

Background: Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

Indication: For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.

Associated Conditions: Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure

Associated Therapies: Positive cardiac inotropic effect, Intravenous inotropic therapy

Clinical Trials

Preoperative Levosimendan in CABG Patients With Poor LV Function

Phase 3

Completed

Conditions: Coronary Artery Bypass Grafting
Left Ventricular Dysfonction

Interventions: Drug: levosimendan
Drug: Placebo

First Posted Date: 2014-07-09

Last Posted Date: 2016-02-25

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 335

Registration Number: NCT02184819

Locations: 🇫🇷
Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, France, Paris, France

Levosimendan Versus Dobutamine for Renal Function in Heart Failure

Phase 3

Completed

Conditions: Cardiorenal Syndrome

Interventions: Drug: Levosimendan
Drug: Dobutamine

First Posted Date: 2014-05-07

Last Posted Date: 2020-02-25

Lead Sponsor: Göteborg University

Target Recruit Count: 33

Registration Number: NCT02133105

Locations: 🇸🇪
Sahlgrenska University Hospital, Gothenburg, Sweden

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

Phase 3

Completed

Conditions: Coronary Artery Bypass Grafting
Mitral Valve Surgery
Low Cardiac Output Syndrome

Interventions: Drug: Levosimendan
Drug: Placebo

First Posted Date: 2014-01-01

Last Posted Date: 2018-06-21

Lead Sponsor: Tenax Therapeutics, Inc.

Target Recruit Count: 882

Registration Number: NCT02025621

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Duke University Hospital, Raleigh, North Carolina, United States
🇺🇸
Iowa Heart Center/ Mercy Medical Center, West Des Moines, Iowa, United States

and more 57 locations

Levosimendan Versus Dobutamine in Cardiopatic Patients Undergoing Major Non Cardiac Surgery

Phase 4

Conditions: Cardiovascular Diseases

Interventions: Drug: Dobutamine
Drug: Levosimendan

First Posted Date: 2013-12-17

Last Posted Date: 2013-12-17

Lead Sponsor: Azienda Policlinico Umberto I

Target Recruit Count: 40

Registration Number: NCT02012946

Locations: 🇮🇹
Francesco Pugliese, Rome, Italy

The Effects of Levosimendan During Mitral Valve Surgery

Phase 4

Completed

Conditions: Mitral Valve Stenosis With Incompetence or Regurgitation

Interventions: Drug: Levosimendan
Drug: Dobutamine

First Posted Date: 2013-10-25

Last Posted Date: 2013-10-25

Lead Sponsor: Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital

Target Recruit Count: 140

Registration Number: NCT01969071

Locations: 🇹🇷
Kartal Kosuyolu High Speciality Training and Research Hospital, Istanbul, Turkey

Effects of Levosimendan on Diaphragm Function in Mechanically Ventilated Patients

Phase 2

Conditions: Weaning Failure
Muscle Weakness Conditions

Interventions: Drug: Placebo
Drug: Levosimendan

First Posted Date: 2012-11-04

Last Posted Date: 2015-06-10

Lead Sponsor: University Medical Center Nijmegen

Target Recruit Count: 42

Registration Number: NCT01721434

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

Levosimendan in Acute Kidney Injury Study

Phase 2

Conditions: Acute Kidney Injury

Interventions: Drug: Conventional therapy
Drug: Levosimendan

First Posted Date: 2012-11-01

Last Posted Date: 2016-09-27

Lead Sponsor: VieCuri Medical Centre

Target Recruit Count: 68

Registration Number: NCT01720030

Locations: 🇳🇱
VieCuri Medical Center, Venlo, Limburg, Netherlands

Comparison of the Administration of Levosimendan and Placebo in the Preparation of Critical Patients for Heart Surgery

Phase 4

Completed

Conditions: Cardiac Surgery

Interventions: Drug: Levosimendan
Drug: Placebo

First Posted Date: 2012-05-10

Last Posted Date: 2015-03-12

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 30

Registration Number: NCT01595737

Locations: 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Two Inodilators Postsurgery in Neonates

Phase 1

Completed

Conditions: Low Cardiac Output Syndrome

Interventions: Drug: Milrinone
Drug: Levosimendan

First Posted Date: 2012-04-12

Last Posted Date: 2012-04-12

Lead Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz

Target Recruit Count: 20

Registration Number: NCT01576094

Locations: 🇪🇸
Hospital Universitario La Paz, Madrid, Spain

Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Levosimendan

First Posted Date: 2012-02-20

Last Posted Date: 2016-02-17

Lead Sponsor: Parc de Salut Mar

Target Recruit Count: 70

Registration Number: NCT01536132

Locations: 🇪🇸
Hospistal Central Asturias, Oviedo, Asturias, Spain
🇪🇸
Hospital la Fe, Valencia, Spain
🇪🇸
Complexo Hospitalario A Coruña, A Coruña, Spain

and more 10 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy